Literature DB >> 31836104

Perceptual learning in patients with Stargardt disease.

Paola Sasso1, Valeria Silvestri2, Marco Sulfaro2, Andrea Scupola3, Romina Fasciani3, Filippo Amore2.   

Abstract

OBJECTIVE: To evaluate the efficacy of Perceptual Learning in improving the peripheral reading performance of patients with Stargardt disease (STGD).
DESIGN: Prospective observational randomized study. PARTICIPANTS: Fourteen consecutive patients (7 females, 7 males; median age of 50.4 ± 12.8 years) with STGD were analyzed and divided into two groups: Group A received "Win-flash" as Perceptual Learning training and Group B was used as control.
METHODS: Subjects underwent an ophthalmic evaluation at baseline, after perceptual learning training and at 6 months of follow-up. Outcomes measured included reading speed, contrast sensitivity and fixation stability.
RESULTS: Reading speed improved of 51,7% after training in group A. Visual acuity, contrast sensitivity and fixation stability enhanced in group A after training from 0.89 (±0.09) LogMAR to 0.75 (±0.2) LogMAR (t(6)= 3.6, p= 0.001), from 0.8 (±0.3) LogC (0.6 - 0.9) to 1.3 (±0.3) LogC (t(13)=3.17, p= 0.003) and from 59.3 % (± 24.3) to 71.5 % (± 20.4) (t(13)=1.8 p= 0.04), respectively. No changes were found in group B. At 6-monts of follow-up, visual acuity and contrast sensitivity decreased in group A.
CONCLUSIONS: STGD patients receiving "Win-flash training", as PL technique, showed an improvement of reading performance on a real-world task. Early follow-up for perceptual learning re-intervention should be considered. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2019        PMID: 31836104     DOI: 10.1016/j.jcjo.2019.03.012

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  1 in total

1.  Reading with central vision loss: binocular summation and inhibition.

Authors:  Valeria Silvestri; Paola Sasso; Paola Piscopo; Filippo Amore; Stanislao Rizzo; Robert G Devenyi; Luminita Tarita-Nistor
Journal:  Ophthalmic Physiol Opt       Date:  2020-09-04       Impact factor: 3.117

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.